ArticleThe Biochemical journal2003
Synthetic peptides derived from the prosegments of proprotein convertase 1/3 and furin are potent inhibitors of both enzymes.
Article in The Biochemical journal, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 40 citations in OpenAlex.
- A nonsense loss-of-function mutation in PCSK1 contributes to dominantly inherited human obesity.International journal of obesity (2005) · 2015Article
- The zymogen of plasmepsin V from Plasmodium falciparum is enzymatically active.Molecular and biochemical parasitology · 2014Article
- The mechanism by which a propeptide-encoded pH sensor regulates spatiotemporal activation of furin.The Journal of biological chemistry · 2013Article
- The Multi-Leu peptide inhibitor discriminates between PACE4 and furin and exhibits antiproliferative effects on prostate cancer cells.Journal of medicinal chemistry · 2012Article
- Highly potent inhibitors of proprotein convertase furin as potential drugs for treatment of infectious diseases.The Journal of biological chemistry · 2012Article
- Proprotein convertase inhibition results in decreased skin cell proliferation, tumorigenesis, and metastasis.Neoplasia (New York, N.Y.) · 2010Article
- Potent inhibitors of furin and furin-like proprotein convertases containing decarboxylated P1 arginine mimetics.Journal of medicinal chemistry · 2010Article
- A novel enediynyl peptide inhibitor of furin that blocks processing of proPDGF-A, B and proVEGF-C.PloS one · 2009Article
- Synthetic small molecule furin inhibitors derived from 2,5-dideoxystreptamine.Proceedings of the National Academy of Sciences of the United States of America · 2006Article
- Crystallization and preliminary X-ray diffraction study of an active-site mutant of pro-Tk-subtilisin from a hyperthermophilic archaeon.Acta crystallographica. Section F, Structural biology and crystallization communications · 2006Article
- Ca2+-dependent maturation of subtilisin from a hyperthermophilic archaeon, Thermococcus kodakaraensis: the propeptide is a potent inhibitor of the mature domain but is not required for its folding.Applied and environmental microbiology · 2006Article
- Inhibitors of proprotein convertases.Journal of molecular medicine (Berlin, Germany) · 2005Review
- Endo/exo-proteolysis in neoplastic progression and metastasis.Journal of molecular medicine (Berlin, Germany) · 2005Review
- Identification of furin pro-region determinants involved in folding and activation.The Biochemical journal · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Proprotein convertases (PCs) are Ca(2+)-dependent serine proteases of the subtilisin/kexin family which are known specifically to cleave propeptide and proprotein substrates at the C-terminal of R-X-(K/R)-R/ to generate the relevant biologically active peptides. PCs are initially synthesized as enzymically inactive proenzyme forms where the prosegments play an important inhibitory role to the respective enzymes. Here we investigated whether synthetic peptides derived from the pro-region could also represent specific and potent inhibitors. Based upon sequence alignment, secondary structure analysis and hydrophilicity plot, a number of peptides ranging from 8 to 33 residues were selected. These included segments encompassing residues 55-62, 50-62, 39-62, 50-83, 55-83, 64-83 and 74-83 in the pro-mouse PC1/3 sequence and residues 54-62, 48-62 and 39-62 of the pro-human furin sequence. All peptides were prepared by solid-phase FastMoc chemistry, purified by reversed-phase HPLC and characterized by MS and amino acid analysis. These peptides were tested in vitro for inhibitory activity towards recombinant mouse PC1/3 and human furin. Progress-curve and end-time kinetic analysis demonstrated that a number of these peptides, particularly those containing both the primary and the secondary processing sites, displayed strong inhibition of both enzymes with inhibition constants (K (i)) in the high nanomolar range. Unlike the whole propeptide, these small synthetic peptide inhibitors exhibited either true competitive or mixed competitive inhibition, depending on the sequence. Our data revealed further the critical role of the last two basic amino acid residues (e.g. Lys(82)-Arg(83) for the mouse PC1/3 sequence) of the prodomain in imparting a strong anti-convertase activity. The study also establishes the inhibitory potential of certain regions contained within the prosegment of the two convertases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.